Inhibition of DDX3 modulates immune signaling in aggressive breast cancers
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.218065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Farhad Vesuna und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Imaging Research, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine,…. Hauptthemen laut MEDLINE: DEAD-box RNA Helicases, Triple Negative Breast Neoplasms, Inflammatory Breast Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health National Cancer Institute, Emerson Collective LLC.
Abstract (Originalsprache)
Triple-negative breast cancers (TNBCs) and inflammatory breast cancer (IBC) are by far the most deadly among all breast cancer subtypes mainly due to being resistant to current treatments. Existing therapies for TNBC and IBC are inadequate due to a limited number of targetable biomarkers and the heterogeneous nature of this disease. In our ongoing search to identify targetable biomarkers for TNBC and IBC, we have found that a member of the RNA helicase protein family, DDX3, is overexpressed in IBC and can be targeted by a small molecule inhibitor which we rationally synthesized, referred to as RK-33. Preliminary data indicate that RK-33 can efficiently and specifically kill TNBC and IBC cell lines without affecting normal breast cells. In the present study, we demonstrate the effectiveness of targeting DDX3 with RK-33 to induce cell death, decrease mammosphere formation, and alter the self-renewal capacity of IBC cells. Additionally, RK-33 was able to disrupt inflammatory cytokine expression in IBC cells. Furthermore, we show that RK-33 sequesters β-catenin in the cytoplasm and decreases Survivin levels in TNBC cells. Moreover, targeting DDX3 with RK-33 promotes multipolar division, leading to cellular death. Importantly, the use of RK-33 also converts high glycolytic tumors to a low glycolytic state, resulting in decreased lactate levels, inhibiting tumor growth, and activating the immune system in an immunocompetent preclinical model of TNBC. Collectively, our data supports the use of RK-33 as a novel therapeutic option for treating TNBC and IBCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cancer Imaging Research, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. Electronic address: fvesuna1@jhmi.edu.
- Division of Cancer Imaging Research, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. Electronic address: pwinnar1@jhmi.edu.
- Division of Cancer Imaging Research, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. Electronic address: m.r.heermavanvoss@amst…
- Division of Cancer Imaging Research, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. Electronic address: Guus.Bol@ucsf.edu.
- Department of Pathology, University Medical Center Utrecht Cancer Center, 3508 GA, Utrecht, the Netherlands. Electronic address: N.terHoeve@umcutrecht.nl.
- Department of Pathology, University Medical Center Utrecht Cancer Center, 3508 GA, Utrecht, the Netherlands; Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. Electronic…
Förderung
- NCI NIH HHS
- National Institutes of Health National Cancer Institute
- Emerson Collective LLC
- National Institutes of Health
- U.S. Department of Defense
- US Office of Congressionally Directed Medical Research Programs
Zitieren
APA
Vesuna, F., Winnard, P. T., van Voss, M. H., Bol, G. M., Ter Hoeve, N. D., van Diest, P. J., & Raman, V. (2025). Inhibition of DDX3 modulates immune signaling in aggressive breast cancers. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.218065
Vancouver
Vesuna F, Winnard PT, van Voss MH, Bol GM, Ter Hoeve ND, van Diest PJ, et al. Inhibition of DDX3 modulates immune signaling in aggressive breast cancers. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.218065
BibTeX
@article{Vesuna2025,
author = {Vesuna, Farhad and Winnard, Paul T and van Voss, Marise Heerma and Bol, Guus M and Ter Hoeve, Natalie D and van Diest, Paul J and Raman, Venu},
title = {Inhibition of DDX3 modulates immune signaling in aggressive breast cancers},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.218065}
}
EUVIMED